PDCD1 and metastatic neoplasm: Management of patients with advanced-stage, unresectable or metastatic bladder cancer (mBC) has shifted in recent years, with novel therapeutic agents available for clinical use, especially new immune checkpoint inhibitors (ICI) directed at programmed cell-death protein 1 (PD-1) or its ligand (PD-L1) with remarkable survival benefits in selected patients with metastatic disease [1].